Parkinson's Fast Facts The Breakdown.

- More than one million Americans and an even greater number worldwide are living with Parkinson's disease (PD)—a chronic degenerative neurological disorder, typically progressing from mild tremors to complete physical incapacitation.
- There are no known ways to prevent Parkinson's disease or to anticipate who will get it. More than 50,000 new cases are diagnosed each year.
- Age remains the biggest predictor, and while Parkinson's patients tend to be older, an estimated 40 percent are diagnosed under age 60. The incidence of Parkinson's is increasing as the "Baby Boomer" population ages.
- Current treatments only mask PD symptoms while the disease continues to progress. The efficiency of most common therapies diminishes over time, leaving fewer treatment options as the disease advances.

Our goal is to create a tipping point, or critical mass of discovery, so that a cure becomes inevitable.

-Dr. J. William Langston

Ponate For A Cure You Are The Fuel.

Please take a moment to send your gift today.

Any amount will help provide the hope of a cure to the more than one million Parkinson's disease patients and their families.

Here's what to do:

- 1. Accept
- 2. Donate
- 3. Share

Accept the challenge to fuel the fight against Parkinson's disease by donating to The Micheal J. Fox Foundation for Parkinson's Research. Share online that you helped get us to our destination: Cure.

You Drive Us Forward.



Destination: Cure.

The Michael J. Fox Foundation for Parkinson's Research
Attn: Veronique Enos
Grand Central Station, PO Box 4777
New York, NY 10163
1. 800. 708. 7644
www.michaeljfox.org





Our Vision

Steering The Roads Ahead.

Since The Michael J. Fox Foundation for Parkinson's Research (MJFF) began in 2000, we've known that, with proper funding, the cure for Parkinson's disease (PD) is within reach. And our optimism is equal to our impatience.

Our Foundation is built for speed and obsessed with relevance. We approach each challenge of identifying and capitalizing on promising research with an open mind. The money we raise quickly goes to the latest cutting-edge research. As a result, we have been heralded in the scientific community for streamlining the process and compressing the timeline–awarding most grants within six months of announcement. Today, we stand as the single largest funder of Parkinson's research outside of the Federal government.

Recognizing that collaborations reduce costs and increase the amount of funds available for research, we forged relationships with other private funders, as well as with the National Institutes of Health. In addition, our media and advocacy efforts have raised awareness and spurred the government to increase spending and get us that much closer to our destination, a cure, that much quicker.

Our Inspiration

What Accelerates Us.

Today, enormous progress is being made on many neurological fronts, and scientists have a better understanding of how PD affects the brain. This is an exciting time for Parkinson's research, and advances in the study of Parkinson's will benefit related diseases like Alzheimer's, Huntington's and ALS.

But it's the millions of Parkinson's patients
worldwide who drive us forward. PD patients endeavor to live their lives beyond
the potentially limiting effects of the
disease, defining themselves by their
achievements, not by their individual daily struggles
with PD.

Our Approach

The Roadmap.

Tangible proof of our unique approach can be found in our Scientific Advisory Board (SAB), a multidisciplinary, international group of leading Parkinson's researchers and clinicians.

The SAB guides our research efforts in three core areas that span basic and clinical science:

- Detecting and preventing Parkinson's disease.
- Restoring dopamine neurons.
- Reducing complications of treatment.

Our approach that brings together collaborative teams to address the big picture issues that can have a major, immediate impact. Over one million people are living with Parkinson's disease.

Finding a Solution Roads Ahead.

There is much work still to be done, and our next steps are clear. We must continue our aggressive pace of fundraising and our support of cutting-edge research. But while we've been able to fund a significant number of promising research initiatives, limited resources mean that the science is ahead of the money.

With your help, we can match the resources with the scientific opportunities. Then one day soon, we'll be able to say that Parkinson's disease truly is nobody's disease.